购物车
- 全部删除
- 您的购物车当前为空
JPI 547, also known as NOV 1402, is an oral inhibitor of PARP 1/2 and Tankyrase 1/2. JPI-547 demonstrated anti-tumor activity in BRCA-deficient xenograft models as a single-agent and in combination with chemotherapy and immune checkpoint inhibitors.
JPI 547, also known as NOV 1402, is an oral inhibitor of PARP 1/2 and Tankyrase 1/2. JPI-547 demonstrated anti-tumor activity in BRCA-deficient xenograft models as a single-agent and in combination with chemotherapy and immune checkpoint inhibitors.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 12,800 | 8-10周 | |
50 mg | ¥ 16,800 | 8-10周 | |
100 mg | ¥ 21,500 | 8-10周 |
产品描述 | JPI 547, also known as NOV 1402, is an oral inhibitor of PARP 1/2 and Tankyrase 1/2. JPI-547 demonstrated anti-tumor activity in BRCA-deficient xenograft models as a single-agent and in combination with chemotherapy and immune checkpoint inhibitors. |
分子量 | 473.402 |
分子式 | C23H26Cl2N6O |
CAS No. | 2055357-65-6 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容